$FATE News

Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

Fate Therapeutics Presents Updated Phase 1 Clinical Data For FT819, Off-The-Shelf, Available On-Demand, Anti-CD19 CAR T-Cell Product Candidate, In Patients With SLE With Lupus Nephritis At ASN Kidney Week 2026

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates